Significant Weight Loss Achieved with Olatorepatide in Phase III Study Presented at EASD 2026

Overview of Significant Findings from the EASD Conference

The annual meeting of the European Association for the Study of Diabetes (EASD) took place from September 28 to October 2, 2026, in Milan, Italy. During this influential conference, a remarkable study was presented, focusing on the efficacy of Olatorepatide (HS-20094), a dual biased agonist of GLP-1 and GIP receptors, developed by Hansoh Pharma. The phase III trial named LIGHTEN showcased the potential of Olatorepatide in weight management, primarily in overweight and obese adults.

Key Study Details

The LIGHTEN study was a multicenter, randomized, double-blind, placebo-controlled phase III trial involving 604 Chinese adults with either a BMI of over 28 kg/m² or between 24-28 kg/m² alongside at least one weight-related comorbidity. Participants were randomly assigned to subcutaneous injections of Olatorepatide at doses of 5 mg, 10 mg, or 15 mg, or a placebo, administered once weekly for a duration of 48 weeks.

Outcomes and Results

Weight Reduction

Impressively, those receiving a dose of 15 mg of Olatorepatide achieved an average weight reduction of 19.3% by the 48th week, with no plateau in weight loss observed. The waist circumference also saw a significant decrease, averaging 16.0 cm. The findings pointed to a notable possibility of further weight reduction even after the study period, suggesting the potential for extended treatment durations to produce greater outcomes.

Gastrointestinal Tolerance

The study also focused on the safety profile of Olatorepatide, which reported low occurrences of gastrointestinal adverse events. For instance, nausea was experienced by 7.8% and vomiting by 4.9% of participants, reflecting a tolerable side effect profile compared to many current obesity treatments.

Comparative Efficacy

The efficacy estimand indicated mean reductions in body weight of -12.5%, -17.5%, and -19.3% in the groups receiving 5 mg, 10 mg, and 15 mg Olatorepatide, respectively, compared to a mere -2.7% in the placebo group. These differences were statistically significant, highlighting the robust effectiveness of Olatorepatide in promoting significant weight loss among study participants.

A substantial percentage of participants also achieved notable weight loss milestones at the 48-week mark: at least 5% weight loss was seen in 87.3% with 5 mg, 97.2% with 10 mg, and 95.2% with 15 mg, compared to just 28.6% in the placebo group.

Broader Metabolic Benefits

Apart from weight reduction, Olatorepatide positively impacted metabolic parameters, including improvements in blood pressure, lipid profiles, HbA1c levels, and insulin resistance indexes, demonstrating its comprehensive metabolic benefits that extend beyond mere weight loss.

Conclusion and Future Implications

These findings, presented at one of the most prestigious conferences in diabetes and metabolism, reflect the significant promise of Olatorepatide as a groundbreaking therapeutic option for weight management. The positive feedback from the clinical community underscores the potential of Olatorepatide to set a new standard in obesity treatment. Moreover, Hansoh Pharma's ongoing strategic developments to commercialize Olatorepatide hint at its future availability not just in China, but globally, aiming for diabetes management applications too, thus fulfilling unmet needs in the healthcare market.

As the landscape of diabetes and obesity treatment advances, continued research and future studies are expected to explore the broader implications and efficacy of Olatorepatide, reinforcing its role in enhancing patients' quality of life through sustained weight management and improved metabolic health.